VX-702

Catalog No.S6005

VX-702 Chemical Structure

Molecular Weight(MW): 404.3

VX-702 is a highly selective inhibitor of p38α MAPK, 14-fold higher potency against the p38α versus p38β. Phase 2.

Size Price Stock Quantity  
In DMSO USD 64 In stock
USD 70 In stock
USD 110 In stock
USD 370 In stock
USD 670 In stock
Bulk Discount

Free Overnight Delivery on orders over $ 500
Next day delivery by 10:00 a.m. Order now.

Cited by 9 Publications

3 Customer Reviews

  • J Invest Dermatol, 2018, 138(6):1380-1390. VX-702 purchased from Selleck.

    Reduction of IL-10 expression due to p38 inhibition is observed also in CpG-stimulated B cells and using VX-702. B cells were pre-treated with 10 uM of VX-702 for 1 h and stimulated with LPS or CpG for 24 or 48 h. Bar graphs indicate mean (±SEM) IL-10 concentrations at 48 h from n = 4 (LPS) and n = 3 (CpG) experiments. Significant differences against the no inhibitor condition were calculated using a paired Student's t-test and indicated as follows: *p < 0.05, ***p < 0.001.

    Mol Immunol 2014 62(2), 266-76. VX-702 purchased from Selleck.

  •  Bone marrow derived macrophages were pre-treated with the indicated concentrations of VX702 for 1h prior to LPS treatment (100 ng/ml).  TNF-a production was analyzed 24h later.

    Lee lay hoon from National University of Singapore. VX-702 purchased from Selleck.

Purity & Quality Control

Choose Selective p38 MAPK Inhibitors

Biological Activity

Description VX-702 is a highly selective inhibitor of p38α MAPK, 14-fold higher potency against the p38α versus p38β. Phase 2.
Features Highly selective, orally active inhibitor of p38 MAPK.
Targets
p38α [1]
(Cell-free assay)
4 nM-20 nM
In vitro

Pre-incubation of platelets with VX-702 (1 μM) completely or partially inhibits p38 activation (IC50 4 to 20 nM) induced by platelet agonists including thrombin, SFLLRN, AYPGKF, U46619 and collagen. VX-702 shows no effect on platelet aggregation induced by any of the p38 MAPK agonists in the presence or absence of anti-platelet therapies. [1] VX-702 inhibits the production of IL-6, IL-1β and TNFα (IC50 = 59, 122 and 99 ng/mL, respectively) in a dose-dependent manner. [2]

Cell Data
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
HOP-62 cell M4TLVmdzd3e2aDDpcohq[mm2aX;uJIF{e2G7 NXrafpVYUW6qaXLpeIlwdiCxZjDoeY1idiCKT2CtOlIh[2WubDDndo94fGhiaX6gZUBk\WyuII\pZYJqdGm2eTDhd5NigSxiSVO1NF0xNjBzNUSzJO69VQ>? NUTm[|h5W0GQR1XS
human NCI-H720 cell Mn;RS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl? NFf0eJVKdmirYnn0bY9vKG:oIHj1cYFvKE6FST3IO|IxKGOnbHyg[5Jwf3SqIHnuJIEh[2WubDD2bYFjcWyrdImgZZN{[XluIFnDOVA:OC5yMU[4NkDPxE1? M{jEe3NCVkeHUh?=
JVM-2 cell MUDHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>? M3TDfmlvcGmkaYTpc44hd2ZiaIXtZY4hUl[PLUKgZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3ME2wMlA5OyEQvF2= MmfkV2FPT0WU
human NCI-H69 cell M1fPdGdzd3e2aDDpcohq[mm2aX;uJIF{e2G7 Mn;sTY5pcWKrdHnvckBw\iCqdX3hckBPS0lvSE[5JINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZktKEmFNUC9NE4xQTl2MTFOwG0> MoTEV2FPT0WU
human BV-173 cell NE\GOW9Iem:5dHigbY5pcWKrdHnvckBie3OjeR?= MW\Jcohq[mm2aX;uJI9nKGi3bXHuJGJXNTF5MzDj[YxtKGe{b4f0bEBqdiCjIHPlcIwhfmmjYnnsbZR6KGG|c3H5MEBKSzVyPUCuNVE{QDZizszN MlHUV2FPT0WU
human KU812 cell Mn:1S5Jwf3SqIHnubIljcXSrb36gZZN{[Xl? NITvNllKdmirYnn0bY9vKG:oIHj1cYFvKEuXOEGyJINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZktKEmFNUC9NE4yOjR6ODFOwG0> NH3vbpJUSU6JRWK=
human DU-145 cell NIDHOZJIem:5dHigbY5pcWKrdHnvckBie3OjeR?= NHGyNGZKdmirYnn0bY9vKG:oIHj1cYFvKESXLUG0OUBk\WyuIHfyc5d1cCCrbjDhJINmdGxidnnhZoltcXS7IHHzd4F6NCCLQ{WwQVAvOTR3NUSg{txO NUnjZZYyW0GQR1XS
KARPAS-45 cell M2TUd2dzd3e2aDDpcohq[mm2aX;uJIF{e2G7 NYPjUnRpUW6qaXLpeIlwdiCxZjDoeY1idiCNQWLQRXMuPDViY3XscEBoem:5dHigbY4h[SClZXzsJJZq[WKrbHn0fUBie3OjeTygTWM2OD1yLkG0PFI3KM7:TR?= NVXkfHV2W0GQR1XS
human AGS cell MnHHS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl? M1\ZdWlvcGmkaYTpc44hd2ZiaIXtZY4hSUeVIHPlcIwh\3Kxd4ToJIlvKGFiY3XscEB3cWGkaXzpeJkh[XO|YYmsJGlEPTB;MD6xOVI2OSEQvF2= NFTueGRUSU6JRWK=
human MOLT-13 cell NIG2WVJIem:5dHigbY5pcWKrdHnvckBie3OjeR?= NY\qdWRYUW6qaXLpeIlwdiCxZjDoeY1idiCPT1zUMVE{KGOnbHyg[5Jwf3SqIHnuJIEh[2WubDD2bYFjcWyrdImgZZN{[XluIFnDOVA:OC5zNUm4NUDPxE1? MXrTRW5ITVJ?
human NCI-H209 cell MULHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>? Ml;nTY5pcWKrdHnvckBw\iCqdX3hckBPS0lvSEKwPUBk\WyuIHfyc5d1cCCrbjDhJINmdGxidnnhZoltcXS7IHHzd4F6NCCLQ{WwQVAvOTd3ODFOwG0> MmXJV2FPT0WU
human CTV-1 cell MXTHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>? MojETY5pcWKrdHnvckBw\iCqdX3hckBEXFZvMTDj[YxtKGe{b4f0bEBqdiCjIHPlcIwhfmmjYnnsbZR6KGG|c3H5MEBKSzVyPUCuNVg{QDlizszN NVfWOWNQW0GQR1XS
LU-139 cell NFX6RWdIem:5dHigbY5pcWKrdHnvckBie3OjeR?= MkflTY5pcWKrdHnvckBw\iCqdX3hckBNXS1zM{mgZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3ME2wMlE6PDN3IN88US=> M{mxZ3NCVkeHUh?=
ML-2 cell NGHDRoxIem:5dHigbY5pcWKrdHnvckBie3OjeR?= MnTRTY5pcWKrdHnvckBw\iCqdX3hckBOVC1{IHPlcIwh\3Kxd4ToJIlvKGFiY3XscEB3cWGkaXzpeJkh[XO|YYmsJGlEPTB;MD6yNlY3OSEQvF2= MVrTRW5ITVJ?
human K5 cell M2iwb2dzd3e2aDDpcohq[mm2aX;uJIF{e2G7 Ml\FTY5pcWKrdHnvckBw\iCqdX3hckBMPSClZXzsJIdzd3e2aDDpckBiKGOnbHygeoli[mmuaYT5JIF{e2G7LDDJR|UxRTBwMkK5NVch|ryP NITN[ItUSU6JRWK=
human SBC-1 cell NI\UbnNIem:5dHigbY5pcWKrdHnvckBie3OjeR?= NUjIcI0zUW6qaXLpeIlwdiCxZjDoeY1idiCVQlOtNUBk\WyuIHfyc5d1cCCrbjDhJINmdGxidnnhZoltcXS7IHHzd4F6NCCLQ{WwQVAvOjN4MjFOwG0> M1XWe3NCVkeHUh?=
human COR-L88 cell NHHKNWNIem:5dHigbY5pcWKrdHnvckBie3OjeR?= M4fqWWlvcGmkaYTpc44hd2ZiaIXtZY4hS0:ULVy4PEBk\WyuIHfyc5d1cCCrbjDhJINmdGxidnnhZoltcXS7IHHzd4F6NCCLQ{WwQVAvOzN2ODFOwG0> MorLV2FPT0WU
human KY821 cell NGX1eY5Iem:5dHigbY5pcWKrdHnvckBie3OjeR?= NEDPWlFKdmirYnn0bY9vKG:oIHj1cYFvKEu\OEKxJINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZktKEmFNUC9NE4{QTZyMzFOwG0> NFTDbnBUSU6JRWK=
human HCC2218 cell M{n5R2dzd3e2aDDpcohq[mm2aX;uJIF{e2G7 NUXmUGtlUW6qaXLpeIlwdiCxZjDoeY1idiCKQ1OyNlE5KGOnbHyg[5Jwf3SqIHnuJIEh[2WubDD2bYFjcWyrdImgZZN{[XluIFnDOVA:OC52OUeyPEDPxE1? NHLZWplUSU6JRWK=
human ECC10 cell NEX3bJRIem:5dHigbY5pcWKrdHnvckBie3OjeR?= M371ZmlvcGmkaYTpc44hd2ZiaIXtZY4hTUOFMUCgZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3ME2wMlY2Ozh7IN88US=> MnvWV2FPT0WU
human EW-3 cell NV71RolrT3Kxd4ToJIlvcGmkaYTpc44h[XO|YYm= NXGyUnJ2UW6qaXLpeIlwdiCxZjDoeY1idiCHVz2zJINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZktKEmFNUC9NE43PjZzMTFOwG0> M3joXHNCVkeHUh?=
human EW-18 cell NEXTO|FIem:5dHigbY5pcWKrdHnvckBie3OjeR?= MYjJcohq[mm2aX;uJI9nKGi3bXHuJGVYNTF6IHPlcIwh\3Kxd4ToJIlvKGFiY3XscEB3cWGkaXzpeJkh[XO|YYmsJGlEPTB;MD63OFY4QSEQvF2= NV;UeYdoW0GQR1XS
human UACC-257 cell NYjEZ3RTT3Kxd4ToJIlvcGmkaYTpc44h[XO|YYm= M2\SfWlvcGmkaYTpc44hd2ZiaIXtZY4hXUGFQz2yOVch[2WubDDndo94fGhiaX6gZUBk\WyuII\pZYJqdGm2eTDhd5NigSxiSVO1NF0yNjJyM{K2JO69VQ>? MUDTRW5ITVJ?
human G-361 cell NULnTodoT3Kxd4ToJIlvcGmkaYTpc44h[XO|YYm= NHPxRlJKdmirYnn0bY9vKG:oIHj1cYFvKEdvM{[xJINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZktKEmFNUC9NU41QTVzOTFOwG0> MkXlV2FPT0WU
human HMV-II cell NI\ucJRIem:5dHigbY5pcWKrdHnvckBie3OjeR?= MYnJcohq[mm2aX;uJI9nKGi3bXHuJGhOXi2LSTDj[YxtKGe{b4f0bEBqdiCjIHPlcIwhfmmjYnnsbZR6KGG|c3H5MEBKSzVyPUGuO|cyQDRizszN MW\TRW5ITVJ?
human DEL cell MkO1S5Jwf3SqIHnubIljcXSrb36gZZN{[Xl? NGDtdGpKdmirYnn0bY9vKG:oIHj1cYFvKESHTDDj[YxtKGe{b4f0bEBqdiCjIHPlcIwhfmmjYnnsbZR6KGG|c3H5MEBKSzVyPUKuNlA4ODRizszN MmD2V2FPT0WU
human IGROV-1 cell M2Wxe2dzd3e2aDDpcohq[mm2aX;uJIF{e2G7 M3LzbGlvcGmkaYTpc44hd2ZiaIXtZY4hUUeUT2[tNUBk\WyuIHfyc5d1cCCrbjDhJINmdGxidnnhZoltcXS7IHHzd4F6NCCLQ{WwQVIvPDNzOEig{txO NVz1bIlkW0GQR1XS
human SK-OV-3 cell MnXSS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl? MoXSTY5pcWKrdHnvckBw\iCqdX3hckBUUy2RVj2zJINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZktKEmFNUC9Nk43OTZ7NzFOwG0> MmTxV2FPT0WU
human LAMA-84 cell NYjtO4FvT3Kxd4ToJIlvcGmkaYTpc44h[XO|YYm= NV7ZV446UW6qaXLpeIlwdiCxZjDoeY1idiCOQV3BMVg1KGOnbHyg[5Jwf3SqIHnuJIEh[2WubDD2bYFjcWyrdImgZZN{[XluIFnDOVA:Oi55MUK4OEDPxE1? MnLXV2FPT0WU
human NCI-H510A cell MYLHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>? NIf5WZlKdmirYnn0bY9vKG:oIHj1cYFvKE6FST3IOVExSSClZXzsJIdzd3e2aDDpckBiKGOnbHygeoli[mmuaYT5JIF{e2G7LDDJR|UxRTJwOUK1NlYh|ryP NWHaellHW0GQR1XS
human CP66-MEL cell NYfw[Zp3T3Kxd4ToJIlvcGmkaYTpc44h[XO|YYm= MnjvTY5pcWKrdHnvckBw\iCqdX3hckBEWDZ4LV3FUEBk\WyuIHfyc5d1cCCrbjDhJINmdGxidnnhZoltcXS7IHHzd4F6NCCLQ{WwQVIvQTN3NUmg{txO MoC4V2FPT0WU
human HAL-01 cell MonVS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl? MnjqTY5pcWKrdHnvckBw\iCqdX3hckBJSUxvMEGgZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3ME2zMlI4QTF6IN88US=> MYTTRW5ITVJ?
human RS4-11 cell  M1fhUmdzd3e2aDDpcohq[mm2aX;uJIF{e2G7 NW\5SoplUW6qaXLpeIlwdiCxZjDoeY1idiCUU{StNVEh[2WubDDndo94fGhiaX6gZUBk\WyuII\pZYJqdGm2eTDhd5NigSxiSVO1NF0{NjdyNUezJO69VQ>? MYjTRW5ITVJ?
human RPMI-8226 cell NESy[VVIem:5dHigbY5pcWKrdHnvckBie3OjeR?= MXjJcohq[mm2aX;uJI9nKGi3bXHuJHJRVUlvOEKyOkBk\WyuIHfyc5d1cCCrbjDhJINmdGxidnnhZoltcXS7IHHzd4F6NCCLQ{WwQVMvQDJ|N{[g{txO MXzTRW5ITVJ?
human NCI-H82 cell MoPlS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl? NWWwbZBRUW6qaXLpeIlwdiCxZjDoeY1idiCQQ1mtTFgzKGOnbHyg[5Jwf3SqIHnuJIEh[2WubDD2bYFjcWyrdImgZZN{[XluIFnDOVA:Oy56OUOwOUDPxE1? NUW0fm5PW0GQR1XS
human NY cells MoTuS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl? MkTpTY5pcWKrdHnvckBw\iCqdX3hckBPYSClZXzsJIdzd3e2aDDpckBiKGOnbHygeoli[mmuaYT5JIF{e2G7LDDJR|UxRTRwMke2N|ch|ryP NYeyUlhsW0GQR1XS
human MDA-MB-361 cell MluzS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl? NWezUXQ6UW6qaXLpeIlwdiCxZjDoeY1idiCPRFGtUWIuOzZzIHPlcIwh\3Kxd4ToJIlvKGFiY3XscEB3cWGkaXzpeJkh[XO|YYmsJGlEPTB;ND60N|E2QCEQvF2= NXvjZ|l5W0GQR1XS
human MOLT-4 cell MYDHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>? MXLJcohq[mm2aX;uJI9nKGi3bXHuJG1QVFRvNDDj[YxtKGe{b4f0bEBqdiCjIHPlcIwhfmmjYnnsbZR6KGG|c3H5MEBKSzVyPUSuPVkyQTNizszN MkWwV2FPT0WU
human DU-4475 cell MYjHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>? M1HsUmlvcGmkaYTpc44hd2ZiaIXtZY4hTFVvNES3OUBk\WyuIHfyc5d1cCCrbjDhJINmdGxidnnhZoltcXS7IHHzd4F6NCCLQ{WwQVUvODV3NkWg{txO MV;TRW5ITVJ?
human ESS-1 cell MYjHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>? NHG1fWZKdmirYnn0bY9vKG:oIHj1cYFvKEWVUz2xJINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZktKEmFNUC9OU4zQTF5OTFOwG0> NEf6OHBUSU6JRWK=
human NCI-H1299 cell MVrHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>? M{XZTGlvcGmkaYTpc44hd2ZiaIXtZY4hVkOLLVixNlk6KGOnbHyg[5Jwf3SqIHnuJIEh[2WubDD2bYFjcWyrdImgZZN{[XluIFnDOVA:PS53M{CzN{DPxE1? M{\Ed3NCVkeHUh?=
human COLO-684 cell NFq0c|hIem:5dHigbY5pcWKrdHnvckBie3OjeR?= M{nTbGlvcGmkaYTpc44hd2ZiaIXtZY4hS0:OTz22PFQh[2WubDDndo94fGhiaX6gZUBk\WyuII\pZYJqdGm2eTDhd5NigSxiSVO1NF02NjV6MU[1JO69VQ>? Mm\GV2FPT0WU
human MV-4-11 cell M3nLUmdzd3e2aDDpcohq[mm2aX;uJIF{e2G7 NG\uPGlKdmirYnn0bY9vKG:oIHj1cYFvKE2YLUStNVEh[2WubDDndo94fGhiaX6gZUBk\WyuII\pZYJqdGm2eTDhd5NigSxiSVO1NF02NjdzMUm5JO69VQ>? MlHEV2FPT0WU
human D-542MG cell NITZfJlIem:5dHigbY5pcWKrdHnvckBie3OjeR?= M{XodGlvcGmkaYTpc44hd2ZiaIXtZY4hTC13NELNS{Bk\WyuIHfyc5d1cCCrbjDhJINmdGxidnnhZoltcXS7IHHzd4F6NCCLQ{WwQVYvOzl{N{Kg{txO MWjTRW5ITVJ?
human A4-Fuk cell M4LnW2dzd3e2aDDpcohq[mm2aX;uJIF{e2G7 M4izSmlvcGmkaYTpc44hd2ZiaIXtZY4hSTRvRoXrJINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZktKEmFNUC9Ok41OzZ4MjFOwG0> NYe0SZpwW0GQR1XS
human HL-60 cell M4jicGdzd3e2aDDpcohq[mm2aX;uJIF{e2G7 MXzJcohq[mm2aX;uJI9nKGi3bXHuJGhNNTZyIHPlcIwh\3Kxd4ToJIlvKGFiY3XscEB3cWGkaXzpeJkh[XO|YYmsJGlEPTB;Nz61NlIyOiEQvF2= M{\mZXNCVkeHUh?=
human NCI-H526 cell NYXRVXNmT3Kxd4ToJIlvcGmkaYTpc44h[XO|YYm= M2PsO2lvcGmkaYTpc44hd2ZiaIXtZY4hVkOLLVi1NlYh[2WubDDndo94fGhiaX6gZUBk\WyuII\pZYJqdGm2eTDhd5NigSxiSVO1NF04NjV7OECxJO69VQ>? NYr1fXg3W0GQR1XS
human L-363 cell MoH3S5Jwf3SqIHnubIljcXSrb36gZZN{[Xl? MXHJcohq[mm2aX;uJI9nKGi3bXHuJGwuOzZ|IHPlcIwh\3Kxd4ToJIlvKGFiY3XscEB3cWGkaXzpeJkh[XO|YYmsJGlEPTB;Nz63PVI2OiEQvF2= NVuxV4l[W0GQR1XS
human A388 cell M4rDXWdzd3e2aDDpcohq[mm2aX;uJIF{e2G7 NX6wdlF3UW6qaXLpeIlwdiCxZjDoeY1idiCDM{i4JINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZktKEmFNUC9O{45ODN6NDFOwG0> NFz3dGtUSU6JRWK=
human MS-1 NXPyZYdiT3Kxd4ToJIlvcGmkaYTpc44h[XO|YYm= NYPUNHJ4UW6qaXLpeIlwdiCxZjDoeY1idiCPUz2xJINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZktKEmFNUC9O{45OzR4NTFOwG0> NELuXZNUSU6JRWK=
human JAR cell MljUS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl? M33LZ2lvcGmkaYTpc44hd2ZiaIXtZY4hUkGUIHPlcIwh\3Kxd4ToJIlvKGFiY3XscEB3cWGkaXzpeJkh[XO|YYmsJGlEPTB;Nz64OFkzOyEQvF2= NVqz[GNlW0GQR1XS
human TI-73 cell MYjHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>? Mn73TY5pcWKrdHnvckBw\iCqdX3hckBVUS15MzDj[YxtKGe{b4f0bEBqdiCjIHPlcIwhfmmjYnnsbZR6KGG|c3H5MEBKSzVyPUiuNFYzOiEQvF2= NXvZXHJxW0GQR1XS
human CTB-1 cell MVTHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>? NI\LUo1KdmirYnn0bY9vKG:oIHj1cYFvKEOWQj2xJINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZktKEmFNUC9PE4yPzh{NTFOwG0> MVTTRW5ITVJ?
human SK-NEP-1 cell NHrPSpFIem:5dHigbY5pcWKrdHnvckBie3OjeR?= M1TpdGlvcGmkaYTpc44hd2ZiaIXtZY4hW0tvTlXQMVEh[2WubDDndo94fGhiaX6gZUBk\WyuII\pZYJqdGm2eTDhd5NigSxiSVO1NF0yOS5|MEO4JO69VQ>? NXr3ZVlQW0GQR1XS
human HT-29 cell MV3Hdo94fGhiaX7obYJqfGmxbjDhd5NigQ>? M4LpXGlvcGmkaYTpc44hd2ZiaIXtZY4hUFRvMkmgZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3ME2xN{46OTFzIN88US=> MXPTRW5ITVJ?
human NCI-H1092 cell NY\PbFFKT3Kxd4ToJIlvcGmkaYTpc44h[XO|YYm= MX3Jcohq[mm2aX;uJI9nKGi3bXHuJG5EUS2KMUC5NkBk\WyuIHfyc5d1cCCrbjDhJINmdGxidnnhZoltcXS7IHHzd4F6NCCLQ{WwQVE1NjNzODFOwG0> MVHTRW5ITVJ?
human KMOE-2 cell NVfPTmZnT3Kxd4ToJIlvcGmkaYTpc44h[XO|YYm= M2L2O2lvcGmkaYTpc44hd2ZiaIXtZY4hU02RRT2yJINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZktKEmFNUC9NVQvPjF5ODFOwG0> M3u3VXNCVkeHUh?=
human EM-2 cell MmnpS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl? NV3NSI04UW6qaXLpeIlwdiCxZjDoeY1idiCHTT2yJINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZktKEmFNUC9NVUvOjh2MTFOwG0> NVPJVIt6W0GQR1XS
human RT-112 cell MkjTS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl? MUPJcohq[mm2aX;uJI9nKGi3bXHuJHJVNTFzMjDj[YxtKGe{b4f0bEBqdiCjIHPlcIwhfmmjYnnsbZR6KGG|c3H5MEBKSzVyPUG1MlM6QDRizszN MX\TRW5ITVJ?
human DB cell NH:zRnVIem:5dHigbY5pcWKrdHnvckBie3OjeR?= MkfrTY5pcWKrdHnvckBw\iCqdX3hckBFSiClZXzsJIdzd3e2aDDpckBiKGOnbHygeoli[mmuaYT5JIF{e2G7LDDJR|UxRTF3Lki1NVMh|ryP MVXTRW5ITVJ?
human NCI-H1770 cell M2\DOmdzd3e2aDDpcohq[mm2aX;uJIF{e2G7 NV7hN4dxUW6qaXLpeIlwdiCxZjDoeY1idiCQQ1mtTFE4PzBiY3XscEBoem:5dHigbY4h[SClZXzsJJZq[WKrbHn0fUBie3OjeR?= MYnTRW5ITVJ?
human CAL-54 cell MV7Hdo94fGhiaX7obYJqfGmxbjDhd5NigQ>? NH;kXIpKdmirYnn0bY9vKG:oIHj1cYFvKEODTD21OEBk\WyuIHfyc5d1cCCrbjDhJINmdGxidnnhZoltcXS7IHHzd4F6NCCLQ{WwQVE3Njd|IN88US=> NHfwV5RUSU6JRWK=
human NB14 cell M{\uTWdzd3e2aDDpcohq[mm2aX;uJIF{e2G7 NHjmcGtKdmirYnn0bY9vKG:oIHj1cYFvKE6EMUSgZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3ME2xO{43Ozl3IN88US=> MmnnV2FPT0WU
human RPMI-7951 cell NFjkemNIem:5dHigbY5pcWKrdHnvckBie3OjeR?= MX;Jcohq[mm2aX;uJI9nKGi3bXHuJHJRVUlvN{m1NUBk\WyuIHfyc5d1cCCrbjDhJINmdGxidnnhZoltcXS7IHHzd4F6NCCLQ{WwQVE6NjF5OEOg{txO M1LpenNCVkeHUh?=
human T47D cell NF22RmtIem:5dHigbY5pcWKrdHnvckBie3OjeR?= NHO1TZFKdmirYnn0bY9vKG:oIHj1cYFvKFR2N1SgZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3ME2yNU4zOjR|IN88US=> MXfTRW5ITVJ?
human A549 cell NIjudXpIem:5dHigbY5pcWKrdHnvckBie3OjeR?= MmP2TY5pcWKrdHnvckBw\iCqdX3hckBCPTR7IHPlcIwh\3Kxd4ToJIlvKGFiY3XscEB3cWGkaXzpeJkh[XO|YYmsJGlEPTB;MkGuNlgyOSEQvF2= NXfOc4xEW0GQR1XS
human A2780 cell MWHHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>? MYDJcohq[mm2aX;uJI9nKGi3bXHuJGEzPzhyIHPlcIwh\3Kxd4ToJIlvKGFiY3XscEB3cWGkaXzpeJkh[XO|YYmsJGlEPTB;MkGuPFIzPSEQvF2= NXzOTWtjW0GQR1XS
human SK-MEL-24 cell MYrHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>? NYfKVphZUW6qaXLpeIlwdiCxZjDoeY1idiCVSz3NSWwuOjRiY3XscEBoem:5dHigbY4h[SClZXzsJJZq[WKrbHn0fUBie3OjeTygTWM2OD1|Mz6wN|EyKM7:TR?= NILzNG9USU6JRWK=

... Click to View More Cell Line Experimental Data

In vivo The half-life of VX-702 is 16 to 20 hours, with a median clearance of 3.75 L/h and a volume of distribution of 73 L/kg. Both AUC and Cmax values are dose proportional for VX-702, which is predominantly cleared renally. [2] VX-702 (at a dose of 0.1 mg/kg twice daily) has an equivalent effect as that of methotrexate (0.1 mg/kg). In addition, VX-702 (5 mg/kg twice daily) also has an equivalent effect as prednisolone (10 mg/kg once daily), as measured by percentage inhibition of wrist joint erosion and inflammation score. [3] VX-702 selectively inhibits activation of p38 MAPK after ischemia with no effects on ERKs and JNKs. The MI/AAR ratio is significantly reduced in the 50 mg/kg group compared with the 5 mg/kg and vehicle groups.[4]

Protocol

Solubility (25°C)

In vitro DMSO 81 mg/mL (200.34 mM)
Water Insoluble
Ethanol Insoluble
In vivo Add solvents to the product individually and in order(Data is from Selleck tests instead of citations):
30% PEG400+0.5% Tween80+5% propylene glycol
For best results, use promptly after mixing.
30 mg/mL

* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.

Chemical Information

Molecular Weight 404.3
Formula

C19H12F4N4O2

CAS No. 745833-23-2
Storage powder
in solvent
Synonyms N/A

Bio Calculators

Molarity Calculator

Molarity Calculator

Calculate the mass, volume or concentration required for a solution. The Selleck molarity calculator is based on the following equation:

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

  • Mass
    Concentration
    Volume
    Molecular Weight

*When preparing stock solutions, please always use the batch-specific molecular weight of the product found on the via label and MSDS / COA (available on product pages).

Dilution Calculator

Dilution Calculator

Calculate the dilution required to prepare a stock solution. The Selleck dilution calculator is based on the following equation:

Concentration (start) x Volume (start) = Concentration (final) x Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2 ( Input Output )

  • C1
    V1
    C2
    V2

* When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and MSDS / COA (available online).

The Serial Dilution Calculator Equation

  • Serial Dilutions

  • Computed Result

  • C1=C0/X C1: LOG(C1):
    C2=C1/X C2: LOG(C2):
    C3=C2/X C3: LOG(C3):
    C4=C3/X C4: LOG(C4):
    C5=C4/X C5: LOG(C5):
    C6=C5/X C6: LOG(C6):
    C7=C6/X C7: LOG(C7):
    C8=C7/X C8: LOG(C8):
Molecular Weight Calculator

Molecular Weight Calculator

Enter the chemical formula of a compound to calculate its molar mass and elemental composition:

Total Molecular Weight: g/mol

Tip: Chemical formula is case sensitive. C10H16N2O2 c10h16n2o2

Instructions to calculate molar mass (molecular weight) of a chemical compound:

To calculate molar mass of a chemical compound, please enter its chemical formula and click 'Calculate'.

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molecular mass (molecular weight) is the mass of one molecule of a substance and is expressed in the unified atomic mass units (u). (1 u is equal to 1/12 the mass of one atom of carbon-12)
Molar mass (molar weight) is the mass of one mole of a substance and is expressed in g/mol.

Molarity Calculator

Mass Concentration Volume Molecular Weight

Clinical Trial Information

NCT Number Recruitment Conditions Sponsor/Collaborators Start Date Phases
NCT00395577 Completed Rheumatoid Arthritis Vertex Pharmaceuticals Incorporated November 2006 Phase 2
NCT00395577 Completed Rheumatoid Arthritis Vertex Pharmaceuticals Incorporated November 2006 Phase 2
NCT00205478 Completed Rheumatoid Arthritis Vertex Pharmaceuticals Incorporated June 2005 Phase 2
NCT00205478 Completed Rheumatoid Arthritis Vertex Pharmaceuticals Incorporated June 2005 Phase 2

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

  • * Indicates a Required Field

p38 MAPK Signaling Pathway Map

p38 MAPK Inhibitors with Unique Features

Related p38 MAPK Products4

Tags: buy VX-702 | VX-702 supplier | purchase VX-702 | VX-702 cost | VX-702 manufacturer | order VX-702 | VX-702 distributor
×
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID